Consensus Avid Bioservices, Inc.

Equities

CDMO

US05368M1062

Real-time Estimate Cboe BZX 01:19:46 2024-03-28 pm EDT 5-day change 1st Jan Change
6.87 USD -1.58% Intraday chart for Avid Bioservices, Inc. +0.44% +6.15%

Evolution of the average Target Price on Avid Bioservices, Inc.

Price target over the last 5 years

History of analyst recommendation changes

0b0e21c66ee61.LGjpazUBTT5Hp_k_XxvR_SNk0ZQ3OCEyvoCZjCEs7OU.aVzZWGdTFUQswolcLm-YmHQ2iN9iVlZT2-revkoeqax9I5EgGHs8CD7xlg~d61a192b650f6237bee24d1efd6ad4bc
Stephens Adjusts Price Target on Avid Bioservices to $12 From $15, Maintains Overweight Rating MT
Craig-Hallum Adjusts Avid Bioservices' Price Target to $16 From $22, Maintains Buy Rating MT
KeyBanc Cuts Price Target on Avid Bioservices to $14 From $20, Maintains Overweight Rating MT
RBC Cuts Price Target on Avid Bioservices to $7 From $15, Cites Slower Revenue Growth Assumptions Amid 'Challenging' Demand Backdrop; Outperform Kept MT
William Blair Initiates Coverage on Avid Bioservices with Market Perform Rating MT
RBC Cuts Price Target on Avid Bioservices to $15 From $17 Amid 'Mixed' Fiscal Q1 Results, Keeps Outperform Rating MT
Stephens Adjusts Avid Bioservices Price Target to $20 From $24, Maintains Overweight Rating MT
Craig Hallum Adjusts Avid Bioservices Price Target to $22 From $25, Maintains Buy Rating MT
RBC Cuts Price Target on Avid Bioservices to $17 From $20, Cites Softer-Than-Expected Revenue Guidance; Outperform Kept MT
Avid Bioservices Upgraded by KeyBanc to Overweight From Sector Weight, Price Target Set at $20 After Fiscal Q3 Beat; Shares Up Pre-Bell MT
RBC Cuts Price Target on Avid Bioservices to $20 From $22, Notes Fiscal Q2 Adjusted EBITDA Miss, Keeps Outperform Rating MT
RBC Cuts Price Target on Avid Bioservices to $22 From $32, Citing Lower Group Multiples, Maintains Outperform Rating MT
Craig-Hallum Lowers Price Target for Avid Bioservices to $30 From $35, Maintains Buy Rating MT
Stephens Adjusts Avid Bioservices' Price Target to $28 from $31, Keeps Overweight Rating MT
Craig-Hallum Adjusts Price Target on Avid Bioservices to $35 From $29, Keeps Buy Rating MT
RBC Lifts Price Target on Avid Bioservices to $32 From $27, Calls Fiscal Q2 'Impressive Quarter for New Business Wins,' Keeps Outperform MT
KeyBanc Downgrades Avid Bioservices to Sector Weight From Overweight MT
AVID BIOSERVICES : Craig-Hallum Adjusts Price Target on Avid Bioservices to $29 From $21, Maintains Buy Rating MT
AVID BIOSERVICES : KeyBanc Adjusts Avid Bioservices' Price Target to $28 From $22, Reiterates Overweight Rating MT
AVID BIOSERVICES : RBC Raises Price Target on Avid Bioservices to $27 From $21 After Fiscal Q4 Revenue Beat, Maintains Outperform Rating MT
AVID BIOSERVICES : Initiated at Outperform by RBC, Price Target Set at $21 MT
AVID BIOSERVICES : KeyBanc Initiates Avid Bioservices at Overweight with $12 Price Target MT
More recommendations

Analysts' Consensus

Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
5
Last Close Price
6.98 USD
Average target price
12.25 USD
Spread / Average Target
+75.50%
High Price Target
16 USD
Spread / Highest target
+129.23%
Low Price Target
7 USD
Spread / Lowest Target
+0.29%

Consensus detail

Consensus revision (last 18 months)

Analysts covering Avid Bioservices, Inc.

Stephens Inc.
Craig-Hallum
KeyBanc Capital Markets
RBC Capital Markets
William Blair & Co.
Trading Rating
Investor Rating
ESG Refinitiv
D+
More Ratings